These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7318129)

  • 41. Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer.
    Fleming GF; Waggoner SE; Rotmensch J; Skoog LA; Langhauser C
    Gynecol Oncol; 1997 Apr; 65(1):42-5. PubMed ID: 9103389
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Administration of oral etoposide for one year as adjuvant chemotherapy for non-small cell lung cancer-side effect].
    Uchida T; Nakakawaji K; Sakamoto J
    Gan To Kagaku Ryoho; 1996 Dec; 23(14):1967-70. PubMed ID: 8978805
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
    Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
    Slayton RE; Blessing JA; Delgado G
    Cancer Treat Rep; 1982 Aug; 66(8):1669-71. PubMed ID: 7105059
    [No Abstract]   [Full Text] [Related]  

  • 46. Oral etoposide for recurrent/progressive sarcomas of childhood.
    Kebudi R; Görgün O; Ayan I
    Pediatr Blood Cancer; 2004 Apr; 42(4):320-4. PubMed ID: 14966827
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Review of etoposide single-agent activity.
    Schmoll H
    Cancer Treat Rev; 1982 Jun; 9 Suppl():21-30. PubMed ID: 6751532
    [No Abstract]   [Full Text] [Related]  

  • 48. Prolonged oral etoposide for refractory advanced uterine leiomyosarcoma.
    Chantarawiroj P; Tresukosol D; Kudelka AP; Edwards CL; Silva EG; Wharton JT; Kavanagh JJ
    Gynecol Oncol; 1995 Aug; 58(2):248-50. PubMed ID: 7622113
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
    Rose PG; Blessing JA; Van Le L; Waggoner S
    Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lack of severe hypotension with VP-16-213 administered directly lv.
    Cavalli F; Sonntag RW; Ryssel HJ; Brunner KW
    Cancer Treat Rep; 1977 Oct; 61(7):1411. PubMed ID: 589604
    [No Abstract]   [Full Text] [Related]  

  • 51. VP16-213 and cyclophosphamide in advanced breast cancer. A phase II study.
    Estapé J; Cirera L; Millá A; Doncel F
    Cancer Chemother Pharmacol; 1983; 10(3):154-7. PubMed ID: 6861258
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer.
    Ahmann DL; Bisel HF; Eagan RT; Edmonson JH; Hahn RG; O'Connell MJ; Frytak S
    Cancer Treat Rep; 1976 May; 60(5):633-5. PubMed ID: 1036468
    [No Abstract]   [Full Text] [Related]  

  • 53. Etoposide-induced hepatic injury: a potential complication of high-dose therapy.
    Johnson DH; Greco FA; Wolff SN
    Cancer Treat Rep; 1983 Nov; 67(11):1023-4. PubMed ID: 6315228
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PHASE I clinical trial of an oral solution of VP-16-213.
    Nissen NI; Dombernowsky P; Hansen HH; Larsen V
    Cancer Treat Rep; 1976 Jul; 60(7):943-5. PubMed ID: 1009527
    [No Abstract]   [Full Text] [Related]  

  • 55. Phase II study of VP-16-213 versus dianhydrogalactitol in patients with metastatic malignant melanoma.
    Ahmann DL; Bisel HF; Edmonson JH; Hahn RG; O'Connell MJ; Frytak S
    Cancer Treat Rep; 1976 Nov; 60(11):1681-2. PubMed ID: 1021239
    [No Abstract]   [Full Text] [Related]  

  • 56. Phase II study of etoposide in the treatment of esophageal carcinoma.
    Coonley CJ; Bains M; Heelan R; Dukeman M; Kelsen DP
    Cancer Treat Rep; 1983 Apr; 67(4):397-8. PubMed ID: 6850656
    [No Abstract]   [Full Text] [Related]  

  • 57. Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213).
    Creaven PJ; Newman SJ; Selawry OS; Cohen MH; Primack A
    Cancer Chemother Rep; 1974; 58(6):901-7. PubMed ID: 4615787
    [No Abstract]   [Full Text] [Related]  

  • 58. Comparison of the biologic activity of VP-16-213 given iv and orally in capsules or drink ampules.
    Brunner KW; Sonntag RW; Ryssel HJ; Cavalli F
    Cancer Treat Rep; 1976 Sep; 60(9):1377-9. PubMed ID: 1016971
    [No Abstract]   [Full Text] [Related]  

  • 59. A phase II trial of VP 16-213 in adults with refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group study.
    Bennett JM; Lymann GH; Cassileth PA; Glick JH; Oken MM
    Am J Clin Oncol; 1984 Oct; 7(5):471-3. PubMed ID: 6594926
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Podophyllotoxin derivatives VP-16 and VM-26.
    D'Incalci M; Garattini S
    Cancer Chemother Biol Response Modif; 1987; 9():67-70. PubMed ID: 3079416
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.